[go: up one dir, main page]

WO2010080757A3 - Combinations with an alpha-4beta-2 nicotinic agonist - Google Patents

Combinations with an alpha-4beta-2 nicotinic agonist Download PDF

Info

Publication number
WO2010080757A3
WO2010080757A3 PCT/US2010/020118 US2010020118W WO2010080757A3 WO 2010080757 A3 WO2010080757 A3 WO 2010080757A3 US 2010020118 W US2010020118 W US 2010020118W WO 2010080757 A3 WO2010080757 A3 WO 2010080757A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
nicotinic agonist
4beta
alpha
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/020118
Other languages
French (fr)
Other versions
WO2010080757A2 (en
Inventor
Edwin Johnson
Eva Nordstrom
Samatha Louise Budd Haeberlein
Merouane Bencherif
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Gyre Therapeutics Inc
Original Assignee
AstraZeneca AB
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB, Targacept Inc filed Critical AstraZeneca AB
Publication of WO2010080757A2 publication Critical patent/WO2010080757A2/en
Publication of WO2010080757A3 publication Critical patent/WO2010080757A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention related to a combination of (a) a α4β2 nicotinic agonist and (b) a Second Therapeutic Agent, as defined under group A or group B. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders, such as cognitive dysfunction in schizophrenia, dementia and/or Alzheimer's disease or those disorders defined below.
PCT/US2010/020118 2009-01-07 2010-01-05 Combinations with an alpha-4beta-2 nicotinic agonist Ceased WO2010080757A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14295909P 2009-01-07 2009-01-07
US61/142,959 2009-01-07

Publications (2)

Publication Number Publication Date
WO2010080757A2 WO2010080757A2 (en) 2010-07-15
WO2010080757A3 true WO2010080757A3 (en) 2010-12-23

Family

ID=42035948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/020118 Ceased WO2010080757A2 (en) 2009-01-07 2010-01-05 Combinations with an alpha-4beta-2 nicotinic agonist

Country Status (1)

Country Link
WO (1) WO2010080757A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
BRPI0712823A2 (en) 2006-06-23 2012-07-24 Abbott Lab cyclopropyl amine derivatives as h3 histamine receptor modulators
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2018115001A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075110A1 (en) * 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
WO2006114400A1 (en) * 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
WO2007134038A2 (en) * 2006-05-09 2007-11-22 Astrazeneca Ab Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
WO2007134034A1 (en) * 2006-05-09 2007-11-22 Targacept, Inc. Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl] -4-penten-2-amine for the treatment of central nervous system disorders
WO2008034041A2 (en) * 2006-09-15 2008-03-20 Astrazeneca Ab Therapeutic combinations
WO2008073942A2 (en) * 2006-12-12 2008-06-19 Abbott Laboratories Pharmaceutical compositions and their methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
DE69739142D1 (en) 1996-04-23 2009-01-15 Targacept Inc PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF CNS DISEASES
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
TWI454262B (en) 2006-11-02 2014-10-01 Targacept Inc Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075110A1 (en) * 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
WO2006114400A1 (en) * 2005-04-26 2006-11-02 Neurosearch A/S Novel oxadiazole derivatives and their medical use
WO2007134038A2 (en) * 2006-05-09 2007-11-22 Astrazeneca Ab Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
WO2007134034A1 (en) * 2006-05-09 2007-11-22 Targacept, Inc. Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl] -4-penten-2-amine for the treatment of central nervous system disorders
WO2008034041A2 (en) * 2006-09-15 2008-03-20 Astrazeneca Ab Therapeutic combinations
WO2008073942A2 (en) * 2006-12-12 2008-06-19 Abbott Laboratories Pharmaceutical compositions and their methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LETCHWORTH S R ET AL: "An orally active neuronal nicotinic receptor modulator with", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 2003, 1 January 2003 (2003-01-01), pages 1, XP008125807, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
WO2010080757A2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
WO2010080757A3 (en) Combinations with an alpha-4beta-2 nicotinic agonist
WO2007092329A3 (en) Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
TN2018000322A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
WO2010030813A3 (en) Methods for inhibiting ocular angiogenesis
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
MX2010002312A (en) Triazolopyridine compounds and their use as ask inhibitors.
WO2010006130A3 (en) Pde-10 inhibitors
WO2012080727A3 (en) Casein kinase 1delta (ck1delta) inhibitors
IL208673A (en) Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2006121560A3 (en) Methods and compositions for treatment of cns disorders
CL2010000129A1 (en) Compounds derived from substituted fused benzazepines, acetylcholine receptor modulators; pharmaceutical composition; preparation procedure; and its use in the treatment of CNS disorders such as schizophrenia, dementia, Alzheimer's disease, multiple sclerosis, among others.
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
HK1206597A1 (en) Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
WO2009105585A3 (en) Postsynaptically targeted chemodenervation agents and their methods of use
MX2014006752A (en) 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives.
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MX340807B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
MY165209A (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
WO2010120695A3 (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders
PH12020551779A1 (en) Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10700135

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10700135

Country of ref document: EP

Kind code of ref document: A2